____________________________________________________________________________________________
Intended use Measurement of soluble LR11 concentrations in serum, plasma (treated with ethylene diamine tetraacetic acid [EDTA], citrate, or heparin), cerebrospinal fluid, and urine.
Description LR11 (also known as SorLA) was identified by Drs. Saito and Bujo, et al. at Chiba University as a low-density lipoprotein (LDL) receptor gene family member1 and was reported to be specifically expressed in intimal smooth muscle cells in atherosclerotic plaques.2 In addition, the presence of LR11 released from the extracellular membrane surface (also known as soluble LR11) was also detected in blood, and immunoassay with specific antibodies revealed high blood concentrations of soluble LR11 in patients with atherosclerotic disease.3 LR11, on the other hand, is involved in the metabolism of amyloid in neurons, and a large-scale epidemiologic study revealed that the genetic polymorphism of LR11 is associated with the development of Alzheimer’s disease.4 It has been confirmed that the level of soluble LR11 in cerebrospinal fluid is similar to that in blood,3 which highlights the association between soluble LR11 and Alzheimer’s disease.5,6 It has recently been revealed that the expression of LR11 is increased in malignant tumors, especially hematological malignancies including leukemia.7 The presence of soluble LR11 in urine has also been confirmed.
This reagent kit enables quantification of soluble LR11 in blood, cerebrospinal fluid, and urine based on a measurement principle deriving from combination of a surfactant and specific antibodies.